• Profile

Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: The surtime randomized clinical trial

JAMA Dec 18, 2018

Bex A, et al. - Authors examined 458 cases (mean age 60 years) from July 14, 2010, to March 24, 2016 to estimate if a period of sunitinib therapy before cytoreductive nephrectomy (CN) could improve the consequence as compared to immediate CN followed by sunitinib in subjects with primary metastatic renal cell carcinoma (mRCC). Out of 49, 48 participants were given sunitinib in the deferred CN arm and 40 of 50 in the immediate arm. They noted no improvement in deferred CN as per 28-week progression-free rate (PFR) calculations. They observed that it might help in the identification of cases with inherent resistance and proved informative to patients with primary clear cell mRCC requiring sunitinib in taking treatment decisions.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen